Veru Secures Novo Nordisk Supply Agreement for Phase 2b Obesity Trial, Grants Right of First Negotiation
VERU is trading near its 52-week low of $2.05 (9.8% above the low).
Summary
Veru Inc. entered a clinical supply agreement with Novo Nordisk for its Phase 2b obesity study, securing free Wegovy® supply and granting Novo Nordisk a right of first negotiation for future combinations.
Key Events · Product Development and Regulatory · VERU
-
Clinical Supply Agreement with Novo Nordisk
Veru Inc. entered into a clinical supply agreement with Novo Nordisk A/S for its Phase 2b PLATEAU clinical study, evaluating enobosarm in combination with Wegovy® for obesity.
-
Free Supply of Wegovy®
Novo Nordisk will supply Wegovy® (semaglutide for injection) to Veru at no charge for the duration of the Phase 2b PLATEAU study, significantly reducing Veru's trial expenses.
-
Right of First Negotiation Granted
Veru granted Novo Nordisk a right of first negotiation for future development, commercialization, or licensing of enobosarm intellectual property in combination with any Novo Nordisk GLP-1 product.
-
Veru Retains Commercialization Rights
Veru maintains full global development and commercialization rights to enobosarm, ensuring control over its primary asset.
Analysis · VERU · Life Sciences
This agreement with Novo Nordisk is a significant positive development for Veru, a small biotech company that recently reiterated a going concern warning. Securing free supply of Wegovy®, a leading GLP-1 RA, for its Phase 2b PLATEAU clinical study substantially reduces Veru's trial costs and provides external validation for its enobosarm combination therapy in obesity. The inclusion of a 'right of first negotiation' for Novo Nordisk on future combinations indicates a strategic interest from a major pharmaceutical player, potentially paving the way for a future partnership or licensing deal if the trial is successful. This strengthens Veru's financial position and clinical program credibility.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VERU was trading at $2.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $36.1M. The 52-week trading range was $2.05 to $7.40. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.